Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06408194 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Name: Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies — clinical trial record (NCT06408194)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorStanford University

Started2024-05-13

View on ClinicalTrials.gov ↗

The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42 days after an infusion of a commercial CAR called Tisagenlecleucel, to children and young adults with relapsed or refractory B-cell leukemia.

Amendment history 3 changes detected by DataLookout

2026-09-02

Primary completion pushed: 2026-07 → 2027-02

2026-09-02

Completion pushed: 2026-07 → 2027-02

2026-07-03

Enrollment increased: 20 → 28 participants

Trial Details

NCT Number	NCT06408194
Lead Sponsor	Stanford University
Conditions	Leukemia, Acute Lymphoblastic Leukemia
Enrollment	28 participants
Start Date	2024-05-13
Primary Completion	2027-02 (estimated)
Study Completion	2027-02 (estimated)
Updated on ClinicalTrials.gov	2026-09-01